标准化癌症免疫疗法：阻断唾液酸结合免疫球蛋白样凝集素15！ - Suppr

Normalization cancer immunotherapy: blocking Siglec-15!

作者信息

Cao Guangchao, Xiao Zhiqiang, Yin Zhinan

机构信息

1The First Affiliated Hospital, Biomedical Translational Research Institute, School of Pharmacy, Jinan University, Guangzhou, China.

The Tenth People's Hospital of Tongji University, Shanghai, China.

出版信息

Signal Transduct Target Ther. 2019 Apr 19;4:10. doi: 10.1038/s41392-019-0045-x. eCollection 2019.

DOI:10.1038/s41392-019-0045-x

PMID:31016034

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6473001/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/074e/6473001/21f5188ed956/41392_2019_45_Fig1_HTML.jpg

相似文献

Normalization cancer immunotherapy: blocking Siglec-15!

Signal Transduct Target Ther. 2019 Apr 19;4:10. doi: 10.1038/s41392-019-0045-x. eCollection 2019.

Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.

Glycobiology. 2018 Sep 1;28(9):640-647. doi: 10.1093/glycob/cwx108.

Siglec and anti-Siglec therapies.

Curr Opin Chem Biol. 2021 Jun;62:34-42. doi: 10.1016/j.cbpa.2021.01.001. Epub 2021 Feb 16.

Siglec receptors as new immune checkpoints in cancer.

Mol Aspects Med. 2023 Apr;90:101112. doi: 10.1016/j.mam.2022.101112. Epub 2022 Aug 7.

Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9.

Nat Commun. 2021 Feb 24;12(1):1270. doi: 10.1038/s41467-021-21550-4.

Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs).

Dis Markers. 2012;32(3):187-94. doi: 10.3233/DMA-2011-0872.

The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.

Expert Opin Ther Targets. 2019 Oct;23(10):839-853. doi: 10.1080/14728222.2019.1667977. Epub 2019 Sep 23.

Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.

Front Immunol. 2019 May 9;10:1047. doi: 10.3389/fimmu.2019.01047. eCollection 2019.

Tools to study and target the Siglec-sialic acid axis in cancer.

FEBS J. 2021 Nov;288(21):6206-6225. doi: 10.1111/febs.15647. Epub 2020 Dec 21.

Siglec-15 as multifunctional molecule involved in osteoclast differentiation, cancer immunity and microbial infection.

Prog Biophys Mol Biol. 2023 Jan;177:34-41. doi: 10.1016/j.pbiomolbio.2022.10.006. Epub 2022 Oct 18.

引用本文的文献

Anti-Tumor Activities of Anti-Siglec-15 Chimeric Heavy-Chain Antibodies.

Int J Mol Sci. 2025 May 24;26(11):5068. doi: 10.3390/ijms26115068.

Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer.

Front Oncol. 2024 Dec 18;14:1437006. doi: 10.3389/fonc.2024.1437006. eCollection 2024.

Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma.

J Cancer. 2023 Sep 18;14(16):2998-3008. doi: 10.7150/jca.87618. eCollection 2023.

Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas.

J Transl Med. 2023 Sep 6;21(1):599. doi: 10.1186/s12967-023-04489-6.

Sialic acid: an attractive biomarker with promising biomedical applications.

Asian Biomed (Res Rev News). 2022 Aug 31;16(4):153-167. doi: 10.2478/abm-2022-0020. eCollection 2022 Aug.

Transcriptional Regulation of Siglec-15 by ETS-1 and ETS-2 in Hepatocellular Carcinoma Cells.

Int J Mol Sci. 2023 Jan 2;24(1):792. doi: 10.3390/ijms24010792.

The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation.

Cancers (Basel). 2022 Oct 31;14(21):5374. doi: 10.3390/cancers14215374.

Aberrant Sialylation in Cancer: Therapeutic Opportunities.

Cancers (Basel). 2022 Aug 31;14(17):4248. doi: 10.3390/cancers14174248.

Front Pharmacol. 2022 Jun 20;13:937413. doi: 10.3389/fphar.2022.937413. eCollection 2022.

Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma.

Sci Rep. 2022 Jun 21;12(1):10401. doi: 10.1038/s41598-022-13997-2.

本文引用的文献

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.

Nat Med. 2019 Apr;25(4):656-666. doi: 10.1038/s41591-019-0374-x. Epub 2019 Mar 4.

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.

Cell. 2018 Oct 4;175(2):313-326. doi: 10.1016/j.cell.2018.09.035.

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.

What does PD-L1 positive or negative mean?

J Exp Med. 2016 Dec 12;213(13):2835-2840. doi: 10.1084/jem.20161462. Epub 2016 Nov 30.

The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.

Glycobiology. 2013 Feb;23(2):178-87. doi: 10.1093/glycob/cws139. Epub 2012 Oct 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Normalization cancer immunotherapy: blocking Siglec-15!

作者信息

Cao Guangchao, Xiao Zhiqiang, Yin Zhinan

机构信息

1The First Affiliated Hospital, Biomedical Translational Research Institute, School of Pharmacy, Jinan University, Guangzhou, China.

The Tenth People's Hospital of Tongji University, Shanghai, China.

出版信息

Signal Transduct Target Ther. 2019 Apr 19;4:10. doi: 10.1038/s41392-019-0045-x. eCollection 2019.

DOI:10.1038/s41392-019-0045-x

PMID:31016034

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6473001/

Abstract

摘要

相似文献

Normalization cancer immunotherapy: blocking Siglec-15!

Signal Transduct Target Ther. 2019 Apr 19;4:10. doi: 10.1038/s41392-019-0045-x. eCollection 2019.

Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.

Glycobiology. 2018 Sep 1;28(9):640-647. doi: 10.1093/glycob/cwx108.

Siglec and anti-Siglec therapies.

Curr Opin Chem Biol. 2021 Jun;62:34-42. doi: 10.1016/j.cbpa.2021.01.001. Epub 2021 Feb 16.

Siglec receptors as new immune checkpoints in cancer.

Mol Aspects Med. 2023 Apr;90:101112. doi: 10.1016/j.mam.2022.101112. Epub 2022 Aug 7.

Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9.

Nat Commun. 2021 Feb 24;12(1):1270. doi: 10.1038/s41467-021-21550-4.

Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs).

Dis Markers. 2012;32(3):187-94. doi: 10.3233/DMA-2011-0872.

The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.

Expert Opin Ther Targets. 2019 Oct;23(10):839-853. doi: 10.1080/14728222.2019.1667977. Epub 2019 Sep 23.

Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.

Front Immunol. 2019 May 9;10:1047. doi: 10.3389/fimmu.2019.01047. eCollection 2019.

Tools to study and target the Siglec-sialic acid axis in cancer.

FEBS J. 2021 Nov;288(21):6206-6225. doi: 10.1111/febs.15647. Epub 2020 Dec 21.

Siglec-15 as multifunctional molecule involved in osteoclast differentiation, cancer immunity and microbial infection.

Prog Biophys Mol Biol. 2023 Jan;177:34-41. doi: 10.1016/j.pbiomolbio.2022.10.006. Epub 2022 Oct 18.

引用本文的文献

Anti-Tumor Activities of Anti-Siglec-15 Chimeric Heavy-Chain Antibodies.

Int J Mol Sci. 2025 May 24;26(11):5068. doi: 10.3390/ijms26115068.

Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer.

Front Oncol. 2024 Dec 18;14:1437006. doi: 10.3389/fonc.2024.1437006. eCollection 2024.

Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma.

J Cancer. 2023 Sep 18;14(16):2998-3008. doi: 10.7150/jca.87618. eCollection 2023.

Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas.

J Transl Med. 2023 Sep 6;21(1):599. doi: 10.1186/s12967-023-04489-6.

Sialic acid: an attractive biomarker with promising biomedical applications.

Asian Biomed (Res Rev News). 2022 Aug 31;16(4):153-167. doi: 10.2478/abm-2022-0020. eCollection 2022 Aug.

Transcriptional Regulation of Siglec-15 by ETS-1 and ETS-2 in Hepatocellular Carcinoma Cells.

Int J Mol Sci. 2023 Jan 2;24(1):792. doi: 10.3390/ijms24010792.

The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation.

Cancers (Basel). 2022 Oct 31;14(21):5374. doi: 10.3390/cancers14215374.

Aberrant Sialylation in Cancer: Therapeutic Opportunities.

Cancers (Basel). 2022 Aug 31;14(17):4248. doi: 10.3390/cancers14174248.

Front Pharmacol. 2022 Jun 20;13:937413. doi: 10.3389/fphar.2022.937413. eCollection 2022.

Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma.

Sci Rep. 2022 Jun 21;12(1):10401. doi: 10.1038/s41598-022-13997-2.

本文引用的文献

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.

Nat Med. 2019 Apr;25(4):656-666. doi: 10.1038/s41591-019-0374-x. Epub 2019 Mar 4.

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.

Cell. 2018 Oct 4;175(2):313-326. doi: 10.1016/j.cell.2018.09.035.

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.

What does PD-L1 positive or negative mean?

J Exp Med. 2016 Dec 12;213(13):2835-2840. doi: 10.1084/jem.20161462. Epub 2016 Nov 30.

The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.

Glycobiology. 2013 Feb;23(2):178-87. doi: 10.1093/glycob/cws139. Epub 2012 Oct 3.

Normalization cancer immunotherapy: blocking Siglec-15!

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Normalization cancer immunotherapy: blocking Siglec-15!

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献